Résumé
Plus de 21 900 participants issus de plus de 80 pays ont participé cette année à la réunion annuelle de l’AACR qui s’est tenue à Washington DC. Environ 6 400 travaux y ont été présentés, travaux qui abordaient de nombreuses découvertes faites dans les différents domaines de la recherche sur le cancer: prévention, biologie du cancer, études translationnelles et cliniques. De nombreuses études incluant des sciences non biologiques telles que la physique, la chimie, les mathématiques ou la bio-informatique ont également été dévoilées, accroissant la diversité et l’originalité des données présentées. Plus spécifiquement, les découvertes récentes faites dans le domaine de l’immunologie tumorale et de l’immunothérapie ont de nouveau été largement abordées et discutées. À ce sujet, notre compréhension de la réponse immunitaire contre les tissus tumoraux et des mécanismes d’échappement immunitaire mis en jeu s’est fortement accrue ces dernières années. Celle-ci a contribué au développement de nouvelles immunothérapies et à l’identification de nouvelles stratégies permettant d’optimiser l’utilisation de celles déjà existantes. Dans ce numéro spécial d’Oncologie, les jeunes médecins de l’association française AERIO (Association d’enseignement et de recherche des internes d’oncologie), supervisés par des médecinschercheurs, présentent les sujets les plus pertinents présentés lors de la réunion de l’AACR 2017. Cette action fait partie intégrante d’un projet qui permet chaque année à cinq jeunes médecins de participer à cette conférence de premier plan et d’en diffuser, grâce à la rédaction d’articles, les informations clés qui en sont issues auprès des professionnels ayant été dans l’incapacité d’y assister.
Abstract
The Annual American Association for Cancer Research (AACR) meeting for this year was took place at Washington, DC and over 21,900 participants from more than 80 countries attended it. About 6,400 proffered abstracts were presented reporting many advances done across different areas of cancer research: prevention, cancer biology, and clinical and translational studies. Non-biological sciences including physics, chemistry, mathematics, computational biology, and bioinformatics participated to the increased diversity and originality of the presented works. Major discoveries done in the field of tumor immunology and immunotherapy were once again a main focus of the meeting with their broad discussions. In particular, our better understanding of the immune response towards cancer and the mechanisms of immune escape has rapidly grown in the past. This contributed to the development of new immunotherapies and led to the identification of new strategies to better use those that already exist. In this special issue of Oncology, mentoring medical doctors of the French association AERIO (Association d’enseignement et de recherche des internes d’oncologie) describe the most relevant topics presented at the meeting. This mentoring is part of an exciting project wherein five young medical doctors are permitted to participate each year at the annual AACR meeting to report, through the redaction and publication of articles, key information to people who could not attend to the conference.
Références
Porporato PE, Dhup S, Dadhich RK, et al (2011) Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol 2, Doi:10.3389/fphar.2011.00049
Renner K, Singer K, Koehl GE, et al (2017) Metabolic hallmarks of tumor and immune cells in the tumor microenvironment. Front Immunol 8, Doi:10.3389/fimmu.2017.00248
Hall A, Meyle KD, Lange MK, et al (2013) Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene. Oncotarget 4:584–99, Doi:10.18632/oncotarget.965
Mehta RS, Nishihara R, Cao Y, et al (2017) Association of dietary patterns with risk of colorectal cancer subtypes classified by Fusobacterium nucleatum in tumor tissue. JAMA Oncol, Doi: 10.1001/jamaoncol.2016.6374
Galon J, Pagès F, Marincola FM, et al (2012) Cancer classification using the immunoscore: a worldwide task force. J Transl Med 10:205
Obeid M, Tesniere A, Ghiringhelli F, et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nature Med 13:54–61, Doi: 10.1038/nm1523
Pietrocola F, Pol J, Vacchelli E, et al (2016) Caloric restriction mimetics enhance anticancer immunosurveillance. Cancer Cell 30:147–60, Doi:10.1016/j.ccell.2016.05.016
Galluzzi L, Buqué A, Kepp O, et al (2016) Immunogenic cell death in cancer and infectious disease. Nature Rev Immunol 17:97–111, Doi:10.1038/nri.2016.107
Eisenberg T, Abdellatif M, Schroeder S, et al (2016) Cardioprotection and lifespan extension by the natural polyamine spermidine. Nat Med 22:1428–38, Doi:10.1038/nm.4222
Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19:1423–37, Doi:10.1038/nm.3394
Adams JL, Smothers J, Srinivasan R, Hoos A (2015) Big opportunities for small molecules in immuno-oncology. Nature Rev Drug Discov 14:603–22, Doi:10.1038/nrd4596
Daigo K, Inforzato A, Barajon I, et al (2016) Pentraxins in the activation and regulation of innate immunity. Immunol Rev 274:202–17, Doi:10.1111/imr.12476
Bonavita E, Mantovani A, Garlanda C (2015) PTX3 acts as an extrinsic oncosuppressor. Oncotarget 6:32309–10, Doi:10.18632/oncotarget.4845
Sulzmaier FJ, Jean C, Schlaepfer DD (2014) FAK in cancer: mechanistic findings and clinical applications. Nature Rev Cancer 14:598–610, Doi:10.1038/nrc3792
Jiang H, Hegde S, Knolhoff BL, et al (2016) Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med 22:851–60, Doi:10.1038/nm.4123
Kaneda MM, Messer KS, Ralainirina N, et al (2016) PI3K? is a molecular switch that controls immune suppression. Nature 539:437–42, Doi:10.1038/nature19834
De Henau O, Rausch M, Winkler D, et al (2016) Overcoming resistance to checkpoint blockade therapy by targeting PI3K? in myeloid cells. Nature 539:443–7, Doi:10.1038/nature20554
Cassier PA, Italiano A, Gomez-Roca CA, et al (2015) CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a doseescalation and dose-expansion phase I study. Lancet Oncol 16:949–56, Doi:10.1016/S1470-2045(15)00132-1
Aldinucci D, Colombatti A (2014) The inflammatory chemokine CCL5 and cancer progression. Mediators Inflamm 2014:292376, Doi:10.1155/2014/292376
Halama N, Zoernig I, Berthel A, et al (2016) Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients. Cancer Cell 29:587–601, Doi:10.1016/j.ccell.2016.03.005
Zhang Q, Liu L, Gong C, et al (2012) Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PloS One 7:e50946, Doi:10.1371/journal.pone.0050946
Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141:39–51, Doi:10.1016/j.cell.2010.03.014
Hortobagyi GN, Stemmer SM, Burris HA, et al (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375:1738–48, Doi:10.1056/NEJMoa1609709
Bardia A, Mayer IA, Diamond JR, et al (2017) Efficacy and safety of anti-Trop2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J Clin Oncol Doi:10.1200/JCO.2016.70.8297
Lieberman S, Tomer A, Ben-Chetrit A, et al (2016) Population screening for BRCA1/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral. Genet Med, Doi:10.1038/gim.2016.182
Hirsh-Yechezkel G, Chetrit A, Lubin F, et al (2003) Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in Israel. Gynecol Oncol 89:494–8
Domchek SM, Friebel TM, Singer CF, et al (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967–75, Doi: 10.1001/jama.2010.1237
Manchanda R, Legood R, Burnell M, et al (2015) Costeffectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history-based testing. JNCI 107, Doi: 10.1093/jnci/dju380
Chan AT, Giovannucci EL, Meyerhardt JA, et al (2005) Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 294:914–23, Doi: 10.1001/jama.294.8.914
Rothwell PM, Wilson M, Elwin CE, et al (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376:1741–50, Doi: 10.1016/S0140-6736(10)61543-7
Giardiello FM, Hamilton SR, Krush AJ, et al (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313–6, Doi: 10.1056/NEJM199305063281805
Giardiello FM, Yang VW, Hylind LM, et al (2002) Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346:1054–9, Doi: 10.1056/NEJMoa012015
Chan AT, Arber N, Burn J, et al (2012) Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Philadelphia, PA) 5:164–78, Doi: 10.1158/1940-6207.CAPR-11-0391
Steinbach G, Lynch PM, Phillips RKS, et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946–52, Doi: 10.1056/NEJM200006293422603
Samadder NJ, Neklason DW, Boucher KM, et al (2016) Effect of sulindac and erlotinib vs. placebo on duodenal neoplasia in familial adenomatous polyposis: a randomized clinical trial. JAMA 315:1266–75, Doi: 10.1001/jama.2016.2522
Burn J, Bishop DT, Mecklin JP, et al (2008) Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 359:2567–78, Doi: 10.1056/NEJMoa0801297
Burn J, Gerdes AM, Macrae F, et al (2011) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378:2081–7, Doi: 10.1016/S0140-6736(11)61049-0
Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329–33, Doi: 10.1200/JCO.2006.09.1066
Rebbeck TR, Mitra N, Wan F, et al (2015) Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313:1347–61, Doi: 10.1001/jama.2014.5985
Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingooophorectomy in BRCA1 or BRCA2 mutation carriers. JNCI 101:80–7, Doi: 10.1093/jnci/djn442
Parsons DW, Roy A, Yang Y, et al (2016 Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors. JAMA Oncol 2:616–24, Doi: 10.1001/jamaoncol.2015.5699
Easton DF, Pharoah PDP, Antoniou AC, et al (2015) Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med 372:2243–57, Doi: 10.1056/NEJMsr1501341
Tung N, Domchek SM, Stadler Z, et al (2016) Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol 13:581–8, Doi: 10.1038/nrclinonc.2016.90
Schrader KA, Cheng DT, Joseph V, et al (2016) Germline variants in targeted tumor sequencing using matched normal DNA. JAMA Oncol 2:104–11, Doi: 10.1001/jamaoncol.2015.5208
Mucci LA, Hjelmborg JB, Harris JR, et al (2016) Familial risk and heritability of cancer among twins in Nordic countries. JAMA 315:68–76, Doi: 10.1001/jama.2015.17703
Amos CI, Dennis J, Wang Z, et al (2017) The OncoArray consortium: a network for understanding the genetic architecture of common cancers. Cancer Epidemiol Biomarkers Prev 26:126–35, Doi: 10.1158/1055-9965.EPI-16-0106
Pharoah PDP, Antoniou A, Bobrow M, et al (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31:33–6, Doi: 10.1038/ng853
Xu J, Sun J, Zheng SL (2013) Prostate cancer risk-associated genetic markers and their potential clinical utility. Asian J Androl 15:314–22, Doi: 10.1038/aja.2013.42
Pritchard CC, Mateo J, Walsh MF, et al (2016) Inherited DNArepair gene mutations in men with metastatic prostate cancer. N Engl J Med 375:443–53, Doi: 10.1056/NEJMoa1603144
Conran CA, Na R, Chen H, et al (2016) Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer. Asian J Androl 18:520–4, Doi: 10.4103/1008-682X.179527
Al Olama AA, Kote-Jarai Z, Berndt SI, et al (2014) A metaanalysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet 46:1103–9, Doi: 10.1038/ng.3094
Chen H, Liu X, Brendler CB, et al (2016) Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: results from the prostate cancer prevention trial. The Prostate 76:1120–9, Doi: 10.1002/pros.23200
Feng BJ (2017) PERCH: a unified framework for disease gene prioritization. Hum Mutat 38:243–51, Doi: 10.1002/humu.23158
Rausch T, Jones DTW, Zapatka M, et al (2012) Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 148:59–71, Doi: 10.1016/j.cell.2011.12.013
Hettmer S, Archer NM, Somers GR, et al (2014) Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers. Cancer 120:1068–75, Doi: 10.1002/cncr.28507
Fischer NW, Prodeus A, Malkin D, Gariépy J (2016) p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis. Cell Cycle (Georgetown, Tex.) 15:3210–9, Doi: 10.1080/15384101.2016.1241917
Zhu J, Sammons MA, Donahue G, et al (2015) Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature 525:206–11, Doi: 10.1038/nature15251
Samuel N, Wilson G, Lemire M, et al (2016) Genome-wide DNA methylation analysis reveals epigenetic dysregulation of microRNA-34A in TP53-associated cancer susceptibility. J Clin Oncol 34:3697–704, Doi: 10.1200/JCO.2016.67.6940
Savage SA, Alter BP (2009) Dyskeratosis congenita. Hematol Oncol Clin North Am 23:215–31, Doi: 10.1016/j.hoc.2009.01.003
Baird DM (2010) Variation at the TERT locus and predisposition for cancer. Expert Rev Mol Med 12:e16, Doi: 10.1017/S146239941000147X
Zhang J, Walsh MF, Wu G, et al (2015) Germline mutations in predisposition genes in pediatric cancer. N Engl J Med 373:2336–46, Doi: 10.1056/NEJMoa1508054
Slavin TP, Blazer KR, Weitzel JN (2016) When clinical care depends on the answer: the challenges of assessing germline cancer gene variants. J Clin Oncol 34:4061–3, Doi: 10.1200/JCO.2016.69.7151
Vijai J, Topka S, Villano D, et al (2016) A recurrent ERCC3 truncating mutation confers moderate risk for breast cancer. Cancer Discov, Doi: 10.1158/2159-8290.CD-16-0487
Charoentong P, Finotello F, Angelova M, et al (2017) Pan-cancer immunogenomic analyses reveal genotype–immunophenotype relationships and predictors of response to checkpoint blockade. Cell Reports 18:248–62, Doi: 10.1016/j.celrep.2016.12.019
Gulshan V, Peng L, Coram M, et al (2016) Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. JAMA 316:2402–10, Doi: 10.1001/jama.2016.17216
Liu Y, Gadepalli K, Norouzi M, et al (2017) Detecting cancer metastases on gigapixel pathology images. Computer Vision and Pattern Recognition
Author information
Authors and Affiliations
Corresponding authors
About this article
Cite this article
Simmet, V., Gantzer, J., Assoun, S. et al. Congrès l’association américaine de recherche contre le cancer — AACR 2017. Oncologie 19, 209–230 (2017). https://doi.org/10.1007/s10269-017-2720-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10269-017-2720-2